Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

Goldman Sachs initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target Discover the Best Stocks and Maximize ...

Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the ...

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

Piotr Swat / SOPA Images / LightRocket via Getty Images Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that of the previous year.